Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Kyowa Hakko Kogyo Co., Ltd. (OTC: KYKOF).

Full DD Report for KYKOF

You must become a subscriber to view this report.

Recent News from (OTC: KYKOF)

3 Things In Biotech, August 9: Clovis Looks Forward In Ovarian Cancer
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Clovis's portents of irrelevance not recognized by the company, presses on with combo stu...
Source: SeekingAlpha
Date: August, 09 2018 09:53
What Does Breakthrough Therapy Designation Really Mean For My Company?
Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. The world of biotech investing revolves first and foremost around the regulatory agencies like th...
Source: SeekingAlpha
Date: June, 23 2018 09:00
Kyowa Hakko Kogyo Co., Ltd. ADR 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by Kyowa Hakko Kogyo Co., Ltd. ADR in conjunction with their 2017 Q4 earnings Read more ...
Source: SeekingAlpha
Date: February, 09 2018 14:13
Your Daily Pharma Scoop: Omeros If And Buts, Egalet's Oxycodone Success, Auris Flunks Study
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Omeros Corp Today we will cover...
Source: SeekingAlpha
Date: November, 29 2017 07:34
Ardelyx and Kyowa Hakko Kirin inks deal for Tenapanor for Cardiorenal diseases in Japan; ARDX up 13% premarket
Ardelyx (NASDAQ: ARDX ) and Kyowa Hakko Kirin ( OTCPK:KYKOF ) announces that they have entered into a license agreement that provides Kyowa Hakko Kirin with exclusive rights to develop and commercialize Ardelyx's lead investigational product, tenapanor, for the treatment of cardiorenal dis...
Source: SeekingAlpha
Date: November, 28 2017 09:00
FDA grants priority review status to Kyowa Hakko Kirin's BLA for Mogamulizumab for the treatment of CTCL
Kyowa Hakko Kirin ( OTCPK:KYKOF )  announces that the FDA has accepted for review the Biologics License Application (BLA) for Mogamulizumab to treat Cutaneous T-cell Lymphoma (CTCL) in patients who have received at least one prior systemic therapy. More news on: Kyowa Hakko Kogyo...
Source: SeekingAlpha
Date: November, 28 2017 08:22


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on KYKOF.

About Kyowa Hakko Kogyo Co., Ltd. (OTC: KYKOF)

Logo for Kyowa Hakko Kogyo Co., Ltd. (OTC: KYKOF)

Not available


Contact Information



Current Share Structure

  • Market Cap: $11,904,386,340 - 03/09/2018
  • Issue and Outstanding: 576,483,600 - 11/30/2011


Daily Technical Chart for (OTC: KYKOF)

Daily Technical Chart for (OTC: KYKOF)

Stay tuned for daily updates and more on (OTC: KYKOF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: KYKOF)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in KYKOF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of KYKOF and does not buy, sell, or trade any shares of KYKOF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: